Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

Background Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute
myeloid leukaemia characterised by the presence of the PML–RARA fusion transcript. The …

Purpose The initial results of the APL0406 trial showed that the combination of all-trans-
retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and …

The combination of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) has been
shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients …

Purpose This report provides an overview of current childhood cancer statistics to facilitate
analysis of the impact of past research discoveries on outcome and provide essential …

An International Working Group met to revise the diagnostic and response criteria for acute
myelogenous leukemia originally published in 1990, as well as to provide definitions of …

Disseminated intravascular coagulation (DIC) is a syndrome characterized by the systemic
activation of blood coagulation, which generates intravascular fibrin, leading to thrombosis …

Disseminated intravascular coagulation (DIC) is categorized into bleeding, organ failure,
massive bleeding, and non-symptomatic types according to the sum of vectors for …